Scientists probe genetic clues behind blood clot risk in rare bone marrow cancers

NCT ID NCT06480591

First seen Jan 10, 2026 · Last updated May 14, 2026 · Updated 22 times

Summary

This study looks at why people with a CALR gene mutation and a type of blood cancer called myeloproliferative neoplasm (MPN) have a lower risk of dangerous blood clots compared to those with a different mutation (JAK2). Researchers will collect blood samples from 35 adults with CALR-mutated MPN to measure certain immune markers and inflammatory proteins. The goal is to better understand the biology behind clot risk, which may guide future treatments.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELOPROLIFERATIVE NEOPLASM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Atrium Health Levine Cancer

    RECRUITING

    Charlotte, North Carolina, 28204, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Wake Forest Baptist Comprehensive Cancer Center

    RECRUITING

    Winston-Salem, North Carolina, 27157, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.